ANTIBACTERIAL POTENTIAL OF L-TRYPTOPHAN ON EXTENDED-SPECTRUM BETALACTAMASE PRODUCING ESCHERICHIA COLI STRAINS: A PATHOLOGICAL PROMISING APPROACH

Saroj Kumar Sah; Ubaid Rasool; Shanthi B; Jayprakash R; Easwaramoorthy D; Hemalatha S

doi:10.22159/ajpcr.2018.v11i7.25664

Authors

Saroj Kumar Sah school of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600 048, India.
Ubaid Rasool school of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600 048, India.
Shanthi B Department of Microbiology, Tagore Medical College and Hospital, Chennai, India.
Jayprakash R Department of Chemistry, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600 048, India.
Easwaramoorthy D Department of Chemistry, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600 048, India.
Hemalatha S School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600 048, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i7.25664

Keywords:

Escherichia coli, Extended-spectrum beta-lactamase, blaCTX-M-15, L-Tryptophan Schiff base

Abstract

Objective: The main aim of this study was to determine the extended-spectrum beta-lactamase (ESBL) production among 83 isolates of Escherichia coli as well as the antibacterial effect of a novel compound, L-Tryptophan Schiff base, on 10 different ESBL positive strains of E. coli.

Methods: Phenotypic ESBL activity in E. coli was confirmed by combined disc diffusion test according to clinical laboratory standard institute guidelines. Phenotypically positive ESBL clinical isolates were selected for molecular screening for synchronized detection of blaCTX-M-15 gene. Antibacterial activity of L-Tryptophan Schiff base was evaluated against ESBL positive isolates. The effect of L-Tryptophan Schiff base on a polymerase chain reaction (PCR) amplified a product of CTX-M-15 gene was also evaluated.

Results: Antibiotic susceptibility screening showed resistance of ESBL positive isolates in the range of 18â€“96%. Disc diffusion test for phenotypic ESBL detection revealed that 99% (83/83) of isolates showed resistance to third and fourth generation cephalosporins (ceftazidime, cefotaxime, and cefepime) including ampicillin. L-Tryptophan Schiff base showed antimicrobial effect on E. coli. Molecular analysis for ESBL detection showed that 60% of strains were positive for blaCTX-M-15 gene. L-Tryptophan Schiff base also had downregulating effect on CTX-M-15 gene.

Conclusion: This study presented an approach toward finding a suitable drug to reduce the serious infections caused by ESBL positive microorganisms. Phenotypic as well as molecular characterization was performed to get knowledge about the overall behavior of ESBL positive isolates of E. coli. L-Tryptophan Schiff base showed good antibacterial properties against ESBL positive isolates and a downregulating effect on PCR amplified product of CTX-M-15.

Downloads

Download data is not yet available.

References

Bush K. New beta-lactamases in gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-9.

Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A. Impact of carbapenems resistance on the outcome of patientsâ€™ hospital-acquired bacteremia caused by Klebsiella pneumoniae. J Hosp Infect 2013;83:307-13.

Jemima SA, Susan V. Multiplex PCR for blaCTX-M and blaSHV in the extended spectrum beta- lactamase producing Gram-negative isolates. Ind J Med Res 2008;128:313-7.

Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M- beta-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol 2004;42:5715-21.

Paterson DL, Hujer KM, Hujer AM, Yeiser B. The international Klebsiella study group Extended-Spectrum beta-lactamases in Klebsiella pneumoniae Bloodstream isolates from seven countries: Dominance and widespread prevalence of SHV and CTX-M Type beta-lactamases. Antimicrob Agents Chemother 2003;47:3554-60.

Bush K, Jacoby GA. Updated functional classification of beta-lactamases. J Antimicrob Age Chemother 2010;54:969-76.

Jayaprakash R, Saroj KS, Hemalatha S, Easwaramoorthy D. QSAR, brine shrimp lethal assay and antimicrobial studies on synthesized l-tryptophan-2,4-dihydroxy benzaldehyde schiff base. Int J Chem Tech 2016;9:48-54.

Farmer J, Boatwright KD, Jada JM. In: Murray P, Baron EJ, Jorgenesan JH, Landry ML, Pfaller MA, editors. Enterobacteriaceae: Introduction and identification. In The Manual of Clinical Microbiology. Washington DC: ASM Press; 2007.

Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-496.

National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disc Susceptibility tests. Approved standard M2-A5. Vol. M100. Villanova: National Committee for Clinical Laboratory Standards; 2012. p. S17, 22.

Pitout JD, Hamilton N, Church DL, Nordmann P, Poirel L. Development and clinical validation of molecular diagnostic assay to detect CTX-M type beta-lactamases in Enterobacteriaceae. Clin Microbiol Infect 2007;13:291-7.

Rina Y, Dvora KS, Benjamin S. Yeshayahu N. Antibacterial effects of the tellurium compound OTD on E. coli isolates. Arch Microbiol 2014;196:51-61.

Sambrook J, Russel DW. Extracted and purification of plasmid; screening of bacterial colonies by hybridization. In: Molecular cloning: A Laboratory Manual. New York, USA: Cold spring Harbor Laboratory Press; 2001. p. 31-9.

Sridhar PN, Prasad SR, Radhakrishna M, Krishna S. Extended spectrum beta -lactamases Producing Escherichia coli and Klebsiella pneumoniae: A Multi centric study across Karnataka. Journal of Laboratory Physicians 2014;6:7-13.

Ensor VM, Shahid M, Evans JT, Hawkey PM. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006;58:1260-3.

Dhillion RH, Clark J. Extended spectrum beta-lactamase; A Clear and Present Danger. Crit Care Res Pract 2012;2012:625170.

Sandhiya R, Priya RL, Esthermary S. Antibiotic susceptibility pattern and ESBL prevalence in Escherichia coli isolates from pus samples in a tertiary care hospital. Int J Pharm Pharm Sci 2015;7:263-4.

Sejal R, Manita W. Antibacterial activity of green tea extract in combination with cefotaxime on diarrhea causing ESBL producing E. coli. Int J Pharm Pharm Sci 2015;7:258-62.

Harwalkar A, Sataraddi J, Gupta S, Yoganand R. The detection of ESBL-producing Escherichia coli in patients with symptomatic urinary tract infections using different diffusion methods in a rural setting. J Infect Public Health 2013;6:108-14.

Sirot D, De-Champs C, Chanal C. Translocation of antibiotic resistance determinants including an extended-spectrum -lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 1991;35:1576-81.

Iroha IR, Esimone CO, Neumann S, Marlinghaus L. First description of Escherichia coli producing CTX-M-15 ESBL in out-patients from southeastern Nigeria. Ann Clin Microbiol Antimicrob 2012;11:19.

Saroj H, Nita P, Rajendra K, Rajni S. Prevalence and antimicrobial susceptibility of ESBL producing Escherichia coli and Klebsiella pneumoniae isolates in a Tertiary Care Hospital in North-West India. Int J Curr Microbiol Appl Sci 2016;5:430-9.

Suman E, Jose J, Verghese S, Kotain MS. Study of biofilm production in Escherichia coli causing urinary tract infection. Indian J Microbiol 2017;25:305-6.

Poovendran P, Vidhya N, Murgan S. In vitro biofilm formation by uropathogenic Escherichia coli and their antimicrobial susceptibility pattern. Asian Pac J Trop Med 2012;5:210-2.

Sugandha S, Jyotsana A, Bharti M, Richa S. Virulence versus fitness determinants in Escherichia coli isolated from asymptomatic bacteriuria in healthy nonpregnant women. Indian J Med Microbiol 2016;34:46 51.